Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | ALK | Q9UM73 | 7/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.39 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
| ▸ | FLT1 | P17948 | 1/20 | 0.39 |
| ▸ | LTK | P29376 | 1/20 | 0.39 |
| ▸ | GRK5 | P34947 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.39 |
| ▸ | CLK2 | P49760 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5255729 | 0.97 | CHEK1 (0.43) | CHEK1ALKDYRK1APDGFRBAURKA | |
| Trifluoroacetic Acid SCHEMBL5256029 | 0.91 | ALK (0.39) | CHEK1ALKDYRK1APDGFRBAURKA | |
| SCHEMBL3942219 | 0.85 | CHEK1 (0.60) | CHEK1ALKDYRK1APDGFRBAURKA | |
| SCHEMBL3935762 | 0.83 | CHEK1 (0.58) | CHEK1ALKDYRK1APDGFRBAURKA | |
| SCHEMBL6511852 | 0.80 | CHEK1 (0.39) | CHEK1ALKDYRK1APDGFRBAURKA | |
| SCHEMBL4518666 | 0.76 | PDGFRB (0.46) | CHEK1PDGFRBFGFR1FLT1KDR | |
| Trifluoroacetic Acid SCHEMBL5313639 | 0.75 | AR (0.35) | CHEK1ALKDYRK1APDGFRBAURKA | |
| Hydrochloric Acid SCHEMBL7206364 | 0.75 | CHEK1 (0.46) | CHEK1PDGFRBFGFR1FLT1KDR | |
| SCHEMBL4680526 | 0.72 | CHEK1 (0.56) | CHEK1ALKDYRK1APDGFRBAURKA | |
| SCHEMBL4680520 | 0.71 | CHEK1 (0.55) | CHEK1ALKDYRK1APDGFRBAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1458707-B1 | New Indol-2-one derivatives | ASTRAZENECA AB (SE) | 2007-05-02 | — | — | EP | claimed |
| US-7205314-B2 | Compounds for the treatment of dementia related diseases | ASTRAZENECA AB (SE) | 2007-04-17 | — | — | US | claimed |
| US-20050065170-A1 | associated with the inhibition of glycogen synthase kinase-3, prevention and/or treatment of dementia related disease, Alzheimer's Disease etc.; example: 3-[6-(2-Methoxyethoxy)isoquinolin-1-yl]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile | ASTRAZENECA AB (SE) | 2005-03-24 | — | — | US | claimed |
| EP-1458707-A2 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2004-09-22 | — | — | EP | claimed |
| WO-2003053330-A2 | USE OF OXINDOLE DERIVATIVES IN THE TREATMENT OF DEMENTIA RELATED DISEASES, ALZHEIMER’S DISEASE AND CONDITIONS ASSOCIATED WITH GLYCOGEN SYNTHASE KINASE-3 | ASTRAZENECA AB (SE) | 2003-07-03 | — | — | WO | claimed |
| EP-1458707-B1 | New Indol-2-one derivatives | ASTRAZENECA AB (SE) | 2007-05-02 | — | — | EP | disclosed |
| US-7205314-B2 | Compounds for the treatment of dementia related diseases | ASTRAZENECA AB (SE) | 2007-04-17 | — | — | US | disclosed |
| US-20050065170-A1 | associated with the inhibition of glycogen synthase kinase-3, prevention and/or treatment of dementia related disease, Alzheimer's Disease etc.; example: 3-[6-(2-Methoxyethoxy)isoquinolin-1-yl]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile | ASTRAZENECA AB (SE) | 2005-03-24 | — | — | US | disclosed |
| EP-1458707-A2 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003053330-A2 | USE OF OXINDOLE DERIVATIVES IN THE TREATMENT OF DEMENTIA RELATED DISEASES, ALZHEIMER’S DISEASE AND CONDITIONS ASSOCIATED WITH GLYCOGEN SYNTHASE KINASE-3 | ASTRAZENECA AB (SE) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065170-A1 | associated with the inhibition of glycogen synthase kinase-3, prevention and/or treatment of dementia related disease, Alzheimer's Disease etc.; example: 3-[6-(2-Methoxyethoxy)isoquinolin-1-yl]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile | GSK3A, GSK3B, PYGB | CHEK1 641/4885ALK 3843/4885DYRK1A 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.